Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Richard Bergenstal MD

Richard M. Bergenstal MD

Executive Director, International Diabetes Center, Park Nicollet Clinic and HealthPartners Institute, Minneapolis, Minnesota

Dr. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet and HealthPartners Institute in Minneapolis. In 2010, he was the ADA’s, President, Medicine & Science. In 2007, he was ADA’s Outstanding Physician Clinician. In 2019, he received the Diabetes Technology Society Leadership Award.  

Dr. Bergenstal was Assistant Professor at the University of Chicago, before joining the IDC in 1983. He currently serves as a principal investigator for three NIH trials: DCCT (T1D), GRADE (T2D) and FLAIR (NIKKD grant to study the next generation of automated insulin delivery systems). His recent focus has been on standardizing CGM metrics and display (ambulatory glucose profile–AGP Report) and on evaluating strategies to implement CGM and hybrid closed loop therapy in clinical practice. He teaches on new diabetes technologies and team care across the US and globally and has been listed in Best Doctors in America since it began in 1992.


Dr Bergenstal has received research support, consulted, or has been on a scientific advisory board for Abbott Diabetes Care, Ascensia, DexCom, Hygieia, Johnson & Johnson, Lilly, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi and United Healthcare. His technology research is funded in part by NIH/NIDDK. Dr Bergenstal's employer, non-profit HealthPartners Institute, contracts for his services, and no personal income goes to Dr Bergenstal.